Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa plus gemcitabine/cisplatin vs placebo plus gemcitabine/cisplatin in advanced biliary tract cancer
CTR20201010Phase 3Terminated
- Sponsor
- Merck Serono
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bintrafusp alfa in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA), gallbladder cancer, Ampullary cancer (AC), sponsored by Merck Serono. Started Sep 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on CTR20201010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201010.